Tirzepatide (TZT), an antidiabetic medicine that has been found to have substantial heart-protective properties, has become a new opponent of heart failure. The study, published in Cardiovascular Diabetology, was conducted by a team of researchers led by Prof. Giuseppe Paolisso, a professor at UniCamillus University of Rome and a full professor of Internal Medicine at Vanvitelli University in Naples. Using a three-step strategy, the researchers conducted a meta-analysis on TZT's cardiovascular effects, assessed its cardiac protective properties in vitro on human heart cells in the laboratory, and performed a bioinformatic study to establish its mechanism of action. The findings revealed that Tirzepatide reduced the risk of major cardiovascular events by shielding cardiac cells from hypertrophy, fibrosis, and cell death. Furthermore, it improves cardiac contractility. The fact that it is an antidiabetic medication makes this active ingredient doubly valid, considering that diabetic subjects are exposed to an increased risk of developing cardiovascular complications, including heart failure.
|